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Abstract
Background: Pterygium is a common ocular surface disease characterized by fibrovascular invasion of
the cornea and is sight-threatening due to astigmatism, tear film disturbance, or occlusion of the visual axis.
However, the mechanisms for formation and post-surgical recurrence of pterygium are not understood,
and a valid animal model does not exist. Here, we investigated the possible mechanisms of pterygium
pathogenesis and recurrence.
Methods: First we performed a genome wide expression analysis (human Affymetrix Genechip, >22000
genes) with principal component analysis and clustering techniques, and validated expression of key
molecules with PCR. The controls for this study were the un-involved conjunctival tissue of the same eye
obtained during the surgical resection of the lesions. Interesting molecules were further investigated with
immunohistochemistry, Western blots, and comparison with tear proteins from pterygium patients.
Results: Principal component analysis in pterygium indicated a signature of matrix-related structural
proteins, including fibronectin-1 (both splice-forms), collagen-1A2, keratin-12 and small proline rich
protein-1. Immunofluorescence showed strong expression of keratin-6A in all layers, especially the
superficial layers, of pterygium epithelium, but absent in the control, with up-regulation and nuclear
accumulation of the cell adhesion molecule CD24 in the pterygium epithelium. Western blot shows
increased protein expression of beta-microseminoprotein, a protein up-regulated in human cutaneous
squamous cell carcinoma. Gene products of 22 up-regulated genes in pterygium have also been found by
us in human tears using nano-electrospray-liquid chromatography/mass spectrometry after pterygium
surgery. Recurrent disease was associated with up-regulation of sialophorin, a negative regulator of cell
adhesion, and never in mitosis a-5, known to be involved in cell motility.
Conclusion: Aberrant wound healing is therefore a key process in this disease, and strategies in wound
remodeling may be appropriate in halting pterygium or its recurrence. For patients demonstrating a profile
of 'recurrence', it may be necessary to manage as a poorer prognostic case and perhaps, more adjunctive
treatment after resection of the primary lesion.
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Global gene expression has been used successfully to elicit
biological behavior in different soft tissue tumors.[1]
Pterygium as a human disease, noted to be more prevalent
than 20% of some populations,[2,3] is of immense bio-
logical interest for a few reasons.
First, the pathogenesis of this condition is hotly debated.
Hypothesis driven approaches have not resolved the rela-
tive importance of competing mechanisms for this dis-
ease. Theories that have been proposed include
inflammatory influence,[4] degeneration of connective
tissue,[5] genetic instability,[6] angiogenesis,[7] redox-
related toxicity,[8] cellular proliferation,[9] aberration of
apoptosis,[10] exuberant wound healing,[11] altered
lipid metabolism,[12] mast cell infiltration.[13] and stem
cell dysfunction.[5] Conventional approaches to disease
mechanism, by virtue of their narrow focus, were not
helpful to assess relative contribution of widely heteroge-
nous processes. Furthermore, a fundamental issue about
the diseased tissue remains un-resolved in this context:
the origin of the epithelium overlying pterygial lesions,
though suspected to be conjunctival in origin, is not
entirely certain.[14]
Second, the spectrum of tumor size and behavior is tre-
mendous, ranging from the inconspicuous lesion barely
encroaching on the peripheral cornea, to the rapidly grow-
ing, menacing tumors that obscure the visual axes and
threaten vision. In some contexts, additional molecular
events.[15] may drive the original tumor to behave differ-
ently from the original lesion. It is also intriguing that
unlike frank malignancies, these lesions, however fast
growing, do not erode through the full thickness cornea,
highlighting the presence of distinct processes from those
manifested in malignant tumors.
Third, pterygium is a mixed soft tissue tumor that is
strongly associated with non-ionising ultraviolet radia-
tion.[4] Unlike the case of cutaneous melanomas, the cell
type that responded to the environmental trigger may not
be epithelial but rather, the fibro-vascular component[9]
– a truly unusual phenomenon in human tumor biology
because ultraviolet radiation-induced tumors encoun-
tered in humans are epithelial in origin and ultraviolet
radiation effects on keloids, if any, are generally inhibi-
tory.
Lastly, the inability of researchers to discover an analo-
gous tumor in animals or reconstitute the disease in organ
cultures imply that pterygium involves specie-specific
mechanisms mediated by in-vivo cell-cell or cell-matrix
interactions. The molecules involved in this disease may
have therefore arisen from divergent evolution in the
human ocular surface.
In view of the controversies on the multiple mechanisms
of pterygia formation, we advocate an unbiased, global
gene expression approach to decipher the dominant gene
expression patterns that may underlie specific molecular
events of interest. Recently, the genome-wide microarray
data in whole tissue pterygium[16] as well as microarray
data limited to cultured pterygial fibroblasts,[17] have
been published. We have performed a study using gene
microarray on recurrent pterygium, primary pterygium
and un-involved conjunctiva, examined the gene subsets
which were differentially regulated, compared our find-
ings with these previous microarray studies,[16,17] and
discussed some of the findings in the light of a comple-
mentary proteomics approach.[18]
In clinical practice, the treatment of this condition is sur-
gical excision.[14] However, some cases aggressively recur
after surgery.[14] Conjunctival auto-grafting as an adjunc-
tive procedure may reduce recurrence, though the expla-
nation for this is not entirely clear.[14] For these reasons,
we speculate that a non-hypothesis driven approach may
also be useful to discover gene expression signatures that
predispose lesions to a more aggressive phenotype. Such
information will benefit clinicians, who can appropriately
anticipate otherwise 'un-expected' biological behavior in
their treatment of this disorder.
Methods
Materials
Antibodies against MUC5AC, keratin 6 and CD24 were
from Labvision, Neomarkers, Fremont, CA, USA, anti-
MSMB antibodies were from US Biologicals, Massachu-
setts, MA, USA, anti-CEACAM5 and anti-NR4A2 antibod-
ies were from Abcam, Cambridge, UK.
Samples used for the Study
The procurement and use of both human tissues in this
study was in compliance with the tenets of the Declara-
tion of Helsinki. The study was approved by the Institu-
tional Review Board of Singapore Eye Research Institute.
Written informed consent was obtained from donors after
explanation of the nature and possible consequences of
the study. Human tissues samples were obtained from
patients diagnosed with primary pterygium and came
from different races, Chinese, Malay and Indian. All
patients underwent pterygium excision in conjunction
with the use of an upper bulbar conjunctival free autograft
placed over the site of the original lesion. All pterygia
specimens used were nasal pterygia. The whole pterygium
tissue and a small portion of the conjunctival patch
(approx. 1 × 3 mm) from the superotemporal conjunctiva
were collected and were rapidly frozen in liquid nitrogen
after removal and stored at -150°C. For immunohistology
purpose, the samples were collected on ice and embeddedPage 2 of 21
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the laboratory.
Microarray Experiment
The procedure for the microarray experiment has previ-
ously been published.[19] All microarray chips and
related protocols and equipment for the processing of
these chips were from Affymetrix Inc., Santa Clara, CA.
The human genome GeneChip U133A consisting of more
than 22000 probe sets was used for this study.
A group of 8 primary pterygium samples, harvested from
4 males (aged 40 to 50 years old) and 4 females (aged 50
to 60 years old) was used in this experiment. Another
group of 4 control conjunctiva tissues, each pooled from
4 individual samples, was used as controls to the diseased
tissues. Considering that only a tiny piece of the conjunc-
tiva tissue could be obtained from each patient during the
surgery, pooling of 4 conjunctiva tissues was necessary to
obtain enough starting material.
Total RNA was extracted using TRIzol Reagent (Invitrogen,
CA) and purified with RNeasy Mini Kit (Qiagen, Valencia,
CA) according to the manufacturer's instructions. Five
micrograms of each purified RNA sample were prepared
according to the Affymetrix standard protocol. Fifteen
micrograms of biotin-labelled cRNA using BioArray RNA
Transcript Labelling Kit (ENZO Life Sciences, NY) were
fragmented and the appropriate volume injected sepa-
rately into the probe array chips.
The transcripts were hybridized onto the immobilized oli-
gonucleotide sequence on array for 16 hours at 45°C
under 60 rpm rotation using GeneChip Hybridization
Oven 640. Washing and Strepavidin-staining steps were
performed using Affymetrix Fluidics Station 450. The
chips were scanned using GeneChip Scanner3000 and the
image data were further analyzed using Microarray Suite
v.5.0. Data analysis included pre-processing and normali-
zation before identification of differentially expressed
genes. Pre-processing adjusted for non-specific binding
and background noise, whereas normalization removed
systematic variation in the data due to effects other than
biological differences. We used the Robust Multi-array
Average (RMA) model [20] to extract the gene expression
signals from probe intensities without taking the mis-
match probe signals into consideration. Cross-array nor-
malization was performed using the intensity-based log
ratio median method [21] with the first array as the refer-
ence. Gene-level normalization was performed by nor-
malizing all samples to the median of the expression level
of the control (un-involved conjunctiva) samples. The
data were annotated using gene annotation headings, bio-
processes and molecular functions from the NetsAffx
database http://www.affymetrix.com/analysis/index.affx.
Analysis of Microarray Data
The data reported in this study have been deposited in
NCBI's Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/ with GEO series accession
number GSE2513). Data were visualised and explored
using the GeneSpring GX 7.3 platform (Agilent Technol-
ogy, Redwood City, CA).
For selection of differentially expressed genes, the modi-
fied t-statistic (SAM) [22] with 100% of the standard devi-
ation percentile as the fudge constant was used. The
threshold for significantly changed genes was set at a false
discovery rate (FDR) of 5%. After delineating a list of dif-
ferentially expressed genes, we performed various types of
analysis to search for a pattern of global gene expression.
The methods ranged from K-means clustering, to the con-
struction of hierarchical dendrograms on a subset of
genes, as well as the visualisation of gene expression pat-
tern summarised by principal component analysis. In
additional to analysis of differentially expressed genes, we
employed the Gene Set Enrichment Analysis (GSEA)
method for identification of those pathways that were
more affected in pterygium tissues. The goal of GSEA is to
determine whether members of a gene set tend to occur
toward the top or bottom of the list, in which case the
gene set is correlated with the phenotypic class distinc-
tion.[23] In contrast to the methods for extraction of dif-
ferentially expressed genes, GSEA considers the collective
up- or down-regulation of a gene set rather than individ-
ual genes. The GSEA software package downloaded from
the Board Institute's website was used for the identifica-
tion of activated or deactivated pathways in primary ptery-
gial and conjunctival tissues. Microarray data for 8
primary pterygial samples and 4 samples of conjunctival
tissue were used. Various datasets from publicly accessible
databases (Biocarta, STKE, PubMed and KEGG) were dis-
sected into over 300 gene sets. The two phenotypic classes
used were pterygium and uninvolved conjunctiva tissues.
As an independent method of analyzing signaling path-
ways in pterygium, we exported the list of genes signifi-
cantly up-regulated or down-regulated by 2 fold into the
Pathway Studio 5.0 software (Ariadne Genomics Inc,
Rockville, MD). The option 'Find all shortest paths
between selected entities' was used on the up-regulated
and down-regulated genes sequentially. The number of
connectivities was limited to 2 and the genes mapped into
known pathways displayed on a chart, and the relevant
relationships listed in a table. The purpose of performing
this analysis was to identify important upstream regula-
tors of the differentially expressed genes as well as down-
stream effectors, in an unbiased fashion, based on known
biological knowledge.Page 3 of 21
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patients who had undergone surgery for pterygium have
already been described.[18] Wherever possible, the fold
change data for genes corresponding to detected tear pro-
teins were tabulated.
Real Time Reverse Transcription Polymerase Chain 
Reaction
Six pairs of independent pterygium and uninvolved con-
junctiva tissues were used in the real time reverse tran-
scription polymerase chain reaction (qPCR) experiment.
One microgram of the each total RNA preparation was
reverse-transcribed to single stranded cDNAs using an
oligo-dT primer with Superscript II Rnase H Reverse Tran-
scriptase (Invitrogen, USA). Primer pairs specific to each
gene used in the qPCR are listed in Additional file 1. qPCR
was performed using SYBR Green PCR Master Mix
(Applied Biosystems) in an ABI Prism 7700 Sequence
Detection System (Applied Biosystems). The thermal
cycling conditions were as follows: 95°C for 10 min, 45
cycles at 95°C for 30 s and 60°C for 1 min. Data obtained
from qPCR were analyzed using the comparative CT
method as previously described by Livak.[24] Paired t-sta-
tistics with p-value < 0.05 was used to determine whether
the qPCR results in pterygial tissue were significantly dif-
ferent from those in un-involved conjunctiva.
Immunohistochemistry
A separate group of paired pterygial and conjunctival tis-
sue samples from three patients were used for immuno-
histochemistry. Sections were cut at 5 μm thicknesses
from blocks of freshly frozen pterygium and matched un-
involved conjunctiva embedded in the OCT. The post-
fixed sections were incubated with the primary antibody
at 4°C overnight. Specific antibodies against the follow-
ing were used: MUC5AC, MSMB, CD24, CEACAM5, kera-
tin 6 and NR4A2. After 3 washes with PBS, secondary
antibody used was either fluorescein isothiocyanate
(FITC)- or Rhodamine- conjugated anti IgG (Santa Cruz,
USA), incubated with the sections for 40 minutes at room
temperature. After 3 final washes each section was
mounted with in a fluorescence mounting medium
(DAKO, Denmark). Images were captured using a 40×
Achrostigmat lens on an Axioplan2 microscope equipped
with an AxioCam MR camera (Carl Zeiss, Germany).
Results
Global Gene Expression Profiling and analysis of 
pterygium versus conjunctiva
Gene expression analysis
With gene level normalization using un-involved con-
junctival samples as reference, gene expression analysis
showed that a total of 105 probe sets were significantly
changed (p < 0.05) by at least 2 fold in primary pterygial
tissue from uninvolved conjunctiva. Among these, 60
probe sets were up-regulated and 45 probe sets were
down-regulated (Table 1). Without performing gene level
normalization, 114 unique genes out of 156 probe sets
were significantly changed in pterygium. (Figure 1)
Gene Ontology Analysis
All significantly changed genes were categorized based on
biological functions using categories from the GeneOn-
tology database (Figure 2). Among the up-regulated
genes, genes coding for cell adhesion (8), extracellular
matrix (ECM) (7) and structural proteins (8) accounted
for 38% of up-regulated genes. Examples of up-regulated
cell adhesion molecules include CADH11, MCAM, FN1,
CEACAM5, ECM component include COL1A2, COL1A1,
COL4A2, COL6A3 and structural proteins, ACTA2,
KRT12, KRT6, KRT23, SPRR1B and SPRR3. Several of
these genes also encode for proteins involved in wound
healing, including COL6A3, CD24, FN1, KRT6a, TFF1,
SPRR1b, and MUC5AC. Another group of up-regulated
genes is the 'mitogenic proteins' group exemplified by
MSMB, CEACAM5 and CD24.
Some immune response and transcription factors were
down-regulated in primary pterygium. Examples of the
former include immunoglobulin heavy chain genes,
whereas examples of the latter include ATF3, BTG2, ERG1,
FOS, FOSB, JUN, NR4A1 and NR4A2. Other down-regu-
lated genes include those encoding for transport proteins,
ie., HBB and HBD, and those involved in stress-response,
including DUSP1 and GADD45B.
When the composition of the list of significantly changed
genes was studied in terms of certain gene ontology cate-
gories, we observed that there is an over-representation of
such genes compared to their expected frequency, consid-
ering the proportion of the probes representing these
genes present on the chip (Table 2). This suggests that
structural molecules and molecules with transporter activ-
ity play a role in pterygium.
Analysis of enriched pathways
Gene set enrichment analysis (GSEA) was performed
using gene expression data from the conjunctival and pri-
mary pterygium groups (Figure 3). Significantly enriched
pathways in pterygium were related to ECM formation,
tissue invasion, angiogenesis and lipid metabolism. Can-
didate genes found to be involved in the ECM pathway
were cadherins (CDH5 and CDH3), integrins (eg.,
ITGb1), cystatin C (CST3) and intracellular adhesion mol-
ecule 1(ICAM1). Angiogenesis related genes include akt1,
akt2, tyrosine kinase 2 (Tyk2), phosphinositide-3-kinases
(PIK3C2A, PIK3CD, PIK3R1, PIK3R2, PIK3R4) and janus
kinases (JAK1, JAK2). The genes involved in 'tissue inva-
sion' pathways include plasminogen activator and recep-
tor (PLAU, PLAUR), matrix metalloproteinasePage 4 of 21
(page number not for citation purposes)
BMC Medical Genomics 2009, 2:14 http://www.biomedcentral.com/1755-8794/2/14(MMP1,2,9), tissue inhibitor of metalloproteinase 1
(TIMP1, TIMP3), serine (or cysteine) proteinase inhibitor
clade B member 5 (SERPINB5), s100 calcium binding
protein (S100A4), secreted phosphoprotein1 (spp1) and
mucin (MUC1). The lipid formation pathway was also
Table 1: Genes significantly changed by at least 2-fold difference 




Genbank accession Fold change
209125_at KRT6A J00269 6.399
205009_at TFF1 NM_003225 5.671
210297_s_at MSMB U22178 4.175
211719_x_at FN1 BC005858 4.112
212464_s_at FN1 X02761 3.939
216442_x_at FN1 AK026737 3.827
207811_at KRT12 NM_000223 3.781
210495_x_at FN1 AF130095 3.738
207430_s_at MSMB NM_002443 3.732
202310_s_at COL1A1 K01228 3.635
216379_x_at AK000168 3.475
209771_x_at CD24 AA761181 3.42
218990_s_at SPRR3 NM_005416 3.401
201884_at CEACAM5 NM_004363 3.287
214385_s_at MUC5B AI521646 3.244
202404_s_at COL1A2 NM_000089 3.149
205064_at SPRR1B NM_003125 3.053
204777_s_at MAL NM_002371 3.043
211161_s_at AF130082 2.937
219087_at ASPN NM_017680 2.903
214303_x_at MUC5AC AW192795 2.897
209047_at AQP1 AL518391 2.773
213796_at SPRR1A AI923984 2.772
205694_at TYRP1 NM_000550 2.736
214580_x_at KRT6A AL569511 2.645
217272_s_at SERPINB13 AJ001698 2.545
218963_s_at KRT23 NM_015515 2.506
218353_at RGS5 NM_025226 2.476
205547_s_at TAGLN NM_003186 2.467
217388_s_at KYNU D55639 2.441
201438_at COL6A3 NM_004369 2.423
203477_at COL15A1 NM_001855 2.374
203980_at FABP4 NM_001442 2.364
202311_s_at COL1A1 AI743621 2.334
215076_s_at COL3A1 AU144167 2.331
213975_s_at LYZ AV711904 2.322
209071_s_at RGS5 AF159570 2.275
210809_s_at POSTN D13665 2.261
202878_s_at C1QR1 NM_012072 2.242
217528_at CLCA2 BF003134 2.226
204682_at LTBP2 NM_000428 2.21
212190_at SERPINE2 AL541302 2.201
219410_at FLJ10134 NM_018004 2.171
209848_s_at SILV U01874 2.15
204351_at S100P NM_005980 2.114
204971_at CSTA NM_005213 2.092
206427_s_at MLANA U06654 2.088
202917_s_at S100A8 NM_002964 2.084
203382_s_at APOE NM_000041 2.081
211980_at COL4A1 AI922605 2.077
200665_s_at SPARC NM_003118 2.071
201667_at GJA1 NM_000165 2.06
218723_s_at RGC32 NM_014059 2.056
203691_at PI3 NM_002638 2.05
206276_at LY6D NM_003695 2.04
219412_at RAB38 NM_022337 2.04
208982_at PECAM1 AW574504 2.029
203504_s_at ABCA1 NM_005502 2.026
201852_x_at COL3A1 AI813758 2.01
203570_at LOXL1 NM_005576 2.01
Down-regulated in pterygium
Probe ID Gene Genbank accession Fold change
217232_x_at HBB AF059180 0.5
208078_s_at TCF8 NM_030751 0.499
201842_s_at EFEMP1 AI826799 0.496
201008_s_at TXNIP AA812232 0.495
215176_x_at AW404894 0.494
206391_at RARRES1 NM_002888 0.494
212225_at SUI1 AL516854 0.492
201505_at LAMB1 NM_002291 0.488
205979_at SCGB2A1 NM_002407 0.487
209278_s_at TFPI2 L27624 0.482
211003_x_at TGM2 BC003551 0.479
211573_x_at TGM2 M98478 0.479
202431_s_at MYC NM_002467 0.475
213831_at HLA-DQA1 X00452 0.47
210095_s_at IGFBP3 M31159 0.465
206392_s_at RARRES1 NM_002888 0.46
211651_s_at LAMB1 M20206 0.455
201843_s_at EFEMP1 NM_004105 0.443
202081_at IER2 NM_004907 0.439
202340_x_at NR4A1 NM_002135 0.435
200664_s_at DNAJB1 BG537255 0.435
209116_x_at HBB M25079 0.431
215723_s_at PLD1 AJ276230 0.43
205910_s_at CEL NM_001807 0.417
219759_at LRAP NM_022350 0.416
204286_s_at PMAIP1 NM_021127 0.406
206424_at CYP26A1 NM_000783 0.403
206393_at TNNI2 NM_003282 0.396
201466_s_at JUN NM_002228 0.388
201464_x_at JUN BG491844 0.368
212143_s_at IGFBP3 BF340228 0.359
201473_at JUNB NM_002229 0.356
217022_s_at MGC27165 S55735 0.355
201236_s_at BTG2 NM_006763 0.342
204285_s_at PMAIP1 AI857639 0.301
201041_s_at DUSP1 NM_004417 0.296
201044_x_at DUSP1 AA530892 0.265
204622_x_at NR4A2 NM_006186 0.22
201694_s_at EGR1 NM_001964 0.215
204621_s_at NR4A2 AI935096 0.192
213674_x_at IGHM AI858004 0.188
216248_s_at NR4A2 S77154 0.17
202768_at FOSB NM_006732 0.167
202672_s_at ATF3 NM_001674 0.159
209189_at FOS BC004490 0.072
Table 1: Genes significantly changed by at least 2-fold difference 
in pterygium (p < 0.05) (Continued)Page 5 of 21
(page number not for citation purposes)
BMC Medical Genomics 2009, 2:14 http://www.biomedcentral.com/1755-8794/2/14
Page 6 of 21
(page number not for citation purposes)
Differentially expressed transcriptsFigu  1
Differentially expressed transcripts. Heat map showing expression of 156 probe sets in conjunctiva and pterygium. Red 
represents high level of expression, green represents lower level expression and black represents no change.
BMC Medical Genomics 2009, 2:14 http://www.biomedcentral.com/1755-8794/2/14significantly enriched in pterygium tissues, for example,
the sterol regulatory element binding transcription
factor1 (SREBF1), dual specific phosphatase 14
(DUSP14), hexokinase2 (HK2) and the solute carrier fam-
ily 2 member 4 (SLC2A4).
The only significantly enriched pathway in un-involved
conjunctiva was related to apoptosis. The genes in this
pathway include the calpains (CAPN1, CAPN2, CAPN3,
CAPNS1) and bcl-antagonist of cell death (BAD2).
Pathway analysis to identify upstream and downstream signals
Up-regulated genes and down-regulated genes were ana-
lysed in pathway studio. Figure 4 summarised signaling
network that resulted from this analysis. Primary ptery-
gium may be characterized by stress-induced down-regu-
lation of transcription factors (Egr1, Jun and Fos), with
defective wound healing as the major process responsible
for the disease phenotype. Scrutiny of the networks in Fig-
ure 4 illustrates a few other relevant processes: up-regula-
tion of PECAM1 and down-regulation of TFPI-2 may
Biological function of dysfunctional genesF gure 2
Biological function of dysfunctional genes. Pie Charts showing the percentage of genes with different biological functions 
that were dysregulated in pterygium.
Table 2: Proportion of significantly changed genes by functional category.
Gene Ontology (GO) Observed % Expected % p value
Extracellular region (5576) 16.3 5.3 0.00698
Extracellular matrix (31012) 13.95 2.4 0.000503
Intermediate filament cytoskeleton (45111) 6.977 0.53 0.00197
Intermediate filament (5882) 6.977 0.58 0.00197
Muscle development (7517) 6.977 1.16 0.0135
Transporter activity (5215) 23.26 12.06 0.0291
Structural molecule activity (5198) 20.93 5.424 0.000414
Extracellular matrix structural constituents (5210) 9.302 0.675 0.000198
Oxidoreductase activity acting on paired donors (16705) 6.977 0.631 0.0025
Note: This refers to primary pterygium versus control. Only functional categories which represent at least 5% of the significantly changed genes are 
shown. The numbers in the brackets represent the GO category ID.Page 7 of 21
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ulation of DUSP1 and up-regulation of GP75 may con-
tribute to an abnormal response to oxidative stress. The
identities and biological/molecular functions of these
relationships are shown in Additional files 2 and 3.
Clustering analysis
To extract some useful knowledge or patterns from global
gene expression data, we performed a few cluster analyses.
The K-means cluster method was computed using 5 clus-
ters on the 156 gene probes differentially expressed in
pterygium compared to controls, over 1000 iterations.
Table 3 shows the final characteristics of the clusters. Two
clusters contained genes that were down-regulated in
pterygium, whereas three other clusters showed genes that
were up-regulated. Visual examination of the role of these
genes revealed biological functions that are consistent
with the above-mentioned pathway and gene ontology
studies.
To identify co-expressed gene sets or the similarity of sam-
ples, we further performed hierarchical clustering analysis
on the data for the 156 gene probes. Two closely related
clusters of genes up-regulated in conjunctiva was detected
(Figure 5A), and similarly, 2 clusters of up-regulated genes
in pterygium were detected (Figure 5B). Scrutiny of the
composition of these clusters yields a number of cytoskel-
etal proteins, immunoglobulins, cancer markers and tran-
scription factors.
We further performed principal component analysis on
the entire set of genes in the chip, as well as several
selected categories of Gene Ontology previously impli-
cated in the pathogenesis of pterygium (Figure 6) for the
following two purposes: 1. To show the compactness of
the samples (represented by the distance between circles)
in each condition and 2. To reveal the possible existence
of a plane which can separate the 2 conditions. The 3D
scatter plots of the first three prinicipal components show
that the expression of genes coding for ECM component
(Figure 6J) was able to differentiate the conjunctiva and
pterygium samples better than those in the antioxidant
(Figure 6F) and apoptosis (Figure 6G) categories. When
all the genes were included in the analysis (Figure 6A), a
clear plane between the pterygial and conjunctival sam-
ples was not so evident. This may be due to the inclusion
of many genes that were not significantly regulated but
whose expression data contained extensive noise. For this
Gene Set Expression analysisFigure 3
Gene Set Expression analysis. Diagram showing the affected pathways involved in pathogenesis of pterygium by Gene Set 
Expression analysis.Page 8 of 21
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duction' (Figure 6H) being unlikely to play a significant
role in pterygium pathogenesis, acted as a negative con-
trol.
Differences between primary and recurrent pterygium
Recurrent pterygium [see Additional file 4] differs from
primary cases as it has a different morphology and often
worse prognosis. Table 4 shows the genes that were differ-
entially regulated in recurrent compared to primary ptery-
gium. Additional file 5 shows that a large number of genes
in recurrent pterygium were down-regulated or up-regu-
lated relative to primary pterygium and conjunctiva tis-
sues. Since there were a rather large number of
differentially regulated genes, only those with at least 2
fold change between primary and recurrent pterygia are
Signaling in pterygiumFigure 4
Signaling in pterygium. Schematic representation of potential signaling pathways involved in primary pterygium. These path-
ways could be affected in conjunctival epithelial cells, fibroblasts or vascular endothelial cells. Pathways were identified by 
incorporating the microarray results (genes which were differentially expressed between normal conjunctival and pterygium 
tissue) into Pathway Studio. Green symbols represent down-regulation, whereas red symbols represent up-regulation of genes. 
Solid lines represent positive regulation, thin arrow with a cross line represent inhibition. Purple symbols represent intermedi-
ate molecules in the potential pathways that may have altered function, for example, CDKN1A or p21 (Cip) may have reduced 
function due to down-regulated egr1 transcription factor. GP75: Tyrosinase-related protein 1, CSTA: cystatin A, TAGLN: 
transgelin, GJA1: Gap junction protein α-1 or Connexin-43, ABCA1: ATP binding cassette subfamily A1 protein, CEL: carboxyl 
ester lipase, DUSP1: dual specificity phosphatase I, PMAIP1: phorbol-12-myristate-13-acetate-induced protein 1, BTG2: B cell 
translocation gene 2, CYP26A1: cytochrome P450 family 26 A1 isoform, NR4A1 and 4A2: nuclear receptors 4A1 and 2, 
SPARC: secreted protein acidic rich in cysteine, TGM-2: transglutaminase 2, TFPI-2: Tissue factor pathway inhibitor 2 and 
IGFBP3: insulin-like growth factor binding protein 3. Green symbols within the nucleus represent transcription factors genes 
that were depressed, probably due to the upstream stress signaling such as those related to ultraviolet light (not shown). Due 
to quenching effect, there may be an increased in the transcriptional promoter activity of other transcription factors such as 
SP1, CEBP and SP3 (open symbols).Page 9 of 21
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genes are not the same as those up-regulated in primary
pterygium compared to conjunctiva. Examples include
stearoyl-CoA desaturase 5 that converts fatty acids into
monounsaturated forms in the endoplasmic reticulum
and involved in dyslipidemia, the ubiquinol-cytochrome
c reductase involved in the mitochondrial respiratory
chain, the DNA recombination repair protein RAD51, the
neuronal thread protein (AD7C-NTP), which is a extracel-
lular protein involved in apoptosis, and the gene for Med-
iterranean fever (MEFV) which is involved in regulation of
transcription and inflammatory response. Involvement of
the gene for sialophorin (SPN or CD43) and NEK5 (Never
in mitosis gene a) are consistent with increased cell migra-
tion because SPN is a negative regulator of cell adhesion
and NEK5 is involved in microtubule function and motil-
ity. Additional file 6 shows possible mechanisms of ptery-
gium recurrence involving these mediators.
Validation of gene microarray data
Relative quantitative real time polymerase chain reaction
(qPCR) was performed as an independent laboratory
approach to validate the transcriptional level changes in
the microarray experiment. These results (Figure 7) show
that for all genes selected for validation with qPCR, the
direction and magnitude of changes were consistent with
the results obtained from the microarray analysis.
We then addressed the question whether protein levels
were also affected in pterygium. Several proteins were
chosen arbitrarily to address the protein expression levels
as well as the localization in pterygium tissues. Our results
(Figure 8) show that protein expression levels for keratin
6, CEACAM5, CD24, MSMB and MUC5AC were
increased, whereas NR4A2 and IGFBP3 were reduced in
pterygium, consistent with the transcript changes detected
by the microarray analysis. Furthermore, the immunoflu-
orescent staining yielded interesting information about
the localization of these proteins in pterygium. Immun-
ofluorescent staining (Figure 8A) shows that keratin 6a
stained strongly in the superficial layer in pterygial epithe-
lium but not in un-involved conjunctiva. Similarly,
CEACAM5 was detected in the squamous layer of ptery-
gial epithelium but was not detectable in conjunctiva.
There was up-regulation and nuclear accummulation of
the cell adhesion molecule CD24 in the pterygium epithe-
lium, but CD24 was not detectable in conjunctiva. MSMB,
on the other hand, was detected prominently in the basal
epithelial layer of pterygium, with some staining also in
the superficial stromal cells adjacent to the basal epithelia.
Lastly, MUC5AC protein was detected in both pterygial
and conjunctival tissue sections predominantly in goblet
cells. However, the intensity of MUC5AC staining in
pterygium was stronger than that in conjunctiva. IGFBP3,
present in un-involved conjunctival stroma and epithe-
lium, and NR4A2, present in conjunctival epithelium,
were reduced in pterygium (Figure 8B).
The up-regulation of MSMB transcripts (Figure 9A) and
proteins (Figure 9B) was also verified by semi-quantitative
reverse transcription polymerase chain reaction and West-
ern blot respectively.
Comparison of microarray data with tear proteins
Another report from our center has previously docu-
mented the analysis of tear proteins in tears of patients
after surgery for pterygium.[18] Briefly, this study
employed reverse-phase high-pressure liquid chromatog-
raphy followed by tryptic digestion and characterisation
of proteins using nanoLC-nano-ESI-MS/MS. Eleven genes
corresponding to the detected tear proteins were signifi-
cantly up-regulated in pterygium compared to un-
involved conjunctival tissue (Table 5). Examples of the
up-regulated genes were those encoding for prolactin
induced protein I and the S100 A8 proteins. Another
eleven genes corresponding to the detected tear proteins
were found to be down-regulated in pterygium. These
include lipophilin C, ribonuclease 4, complement C3 and
histone 1b. Twenty-nine genes corresponding to detected
tear proteins were not significantly up or down-regulated
in pterygium. Since there were no controls in this
study,[18] it is difficult to interpret some of these findings.
Furthermore it was not possible to compare the microar-
ray results with every instance of the protein data because
more than one type of probe sets may contribute to the
synthesis of the protein and not all gene probe sets have
signal-noise ratio high enough for this analysis.
Table 3: K-means cluster analysis supplemented with GO browser results.
Cluster No of Genes Average Radius Status in pterygium Major function by GO
1 58 2.463 Down-regulated Response to stimulus
2 13 1.803 Up-regulated Metabolism
3 37 1.507 Up-regulated Cell adhesion, response to wounding
4 22 2.357 Up-regulated Lipid related
5 26 1.827 Down-regulated Cell proliferationPage 10 of 21
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Hierarchical clustering analysisFigure 5
Hierarchical clustering analysis. Dendrograms were constructed using hierarchical clustering algorithms, performed on 
the subset of significantly changed genes. The shorter the length of the branches, the more co-expressed the members of the 
genes are. Magnified portions of the dendrograms showing the clusters of co-expression for genes down-regulated (A) and up-
regulated (B) in primary pterygium relative to control. Note that the 2 clusters in A involved transcription factors and immu-
noglobulins, whereas 2 clusters in B were involved in structural proteins and extracellular matrix.
BMC Medical Genomics 2009, 2:14 http://www.biomedcentral.com/1755-8794/2/14Discussion
Major findings
A global gene expression analysis of pterygium showed
distinct differences between primary pterygium and unin-
volved conjunctiva. Several pathways were significantly
affected in pterygium. These were: increase in the produc-
tion of extracellular matrix, structural proteins, mitotic
proteins, and protein involved in tissue invasion.
Recurrent pterygia demonstrated a different signature
composed of other perturbed genes. For example, the
COL4A6 (AL031177) and the RAB6B (BC002510) were
down- and up-regulated respectively in recurrent pterygia
compared to primary pterygia. The former encodes for
one of the 6 subunits of collagen IV, a major component
of the basement membrane, whereas the latter is a RAS
family oncogene. The finding suggests that recurrence is a
distinct biological phenomenon from the formation of
primary pterygium, even though in general, we did not
detect obvious microscopic changes between primary and
recurrent pterygia.
Microarray analysis of gene expression is a useful
approach for understanding the molecular mechanism of
disease. We used both qPCR and immunohistochemistry
to show that both RNA level and protein levels of specific
mediators were dysregulated, validating the results from
the gene microarray approach. Some 22 genes corre-
sponding to tear proteins detected in pterygium subjects
were significantly up or down-regulated in pterygium rel-
ative to conjunctival tissue. Many of the processes discov-
ered in this study are highly novel and were not previously
associated with pterygium, for example, immunohisto-
chemistry show that cell adhesion molecules (ie., CD24)
may be increased but abnormally localized in the nuclei
in pterygium epithelium and therefore cell adhesion
properties may be disturbed. Another example is the evi-
dence for Goblet cell dysfunction. In pterygium, there was
elevation of transcript and protein expression of
Principal component analysisFigure 6
Principal component analysis. Three-D scatter plots constructed from principal component analyses of gene expression 
data. In the scatter plots the first, second and third principal components were plotted on the x, y and z axis respectively. Red 
circles represent conjunctival samples (control) whereas yellow circles denote primary pterygial samples. A. Performed on all 
genes, B-L. Using subsets of Gene Ontology genes corresponding to a biological process or molecular function and J-L. Using 
subsets of Gene Ontology genes corresponding to specific cellular components. Brackets represent the number of genes in the 
overall analysis (A) or in subsets (B-L)Page 12 of 21
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of conjunctival mucous-secreting Goblet cells,[25] and
MSMB is a cutaneous squamous cell carcinoma related
protein[26] that is associated with respiratory tract Goblet
cells.[27]
Comparison with previous studies
The data from a previous study utilized only 2 primary
and 1 recurrent pterygia, with no stratification of data
between the clinical sub-types.[16] This study[16] high-
lighted the up-regulation of 29 genes common to primary
and recurrent pterygium. Our results supported the dys-
regulation of 19 of these genes in pterygium (Table 6), for
example, TRAP100, MIP-4, RBP-1, MAP-17 and PECAM1.
One apparent discrepancy was that the CLIC2 was up-reg-
ulated in our study, but significantly down-regulated in
John-Aryankalayil et al.[16] Discrepancies reflect differ-
ences in study methodology, for example, this study[16]
used an older microarray chip HG_U95Av2, containing
considerably less probes than the U133A; and the earlier
study may have differences in probe, chip or gene-level
normalizations which were not reported. Differences in
normalization may account for the differences in the folds
of change in specific genes between different studies. In
John-Aryankalayil et al's study, although a few up-regulated
genes from different functional categories were tabulated,
Table 4: Distinguishing recurrent from primary pterygia (p < 0.05), list of genes down-regulated or up-regulated by at least 2-fold.
A. Name of down-regulated genes No of folds down-regulated B. Name of up-regulated genes No of folds up-regulated
PSCA -4.34 SCD5 4.05
COL1A1 -4.21 C12orf38 3.12
COL6A2 -3.24 MEFV 3.10
COL3A1 -3.09 UQCRQ 2.68
HDDC2 -2.84 RAD51L3 2.43
ASPN -2.77 SPN 2.36
YWHAE -2.66 AD7C-NTP 2.19
KRT7 -2.65 NEK5 2.18
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sion or relative contribution of broad biological proc-
esses.[16] Unlike this study, we did not restrict to listing
differentially expressed genes by fold change.
Previous studies[28,29] have shown that gene expression
profiles in tumor and wound response were similar, lend-
ing support to our opinion that wound response is the
major theme in global pterygial gene expression.
Possible mechanisms of pterygia formation
We believe that our data support a predominantly wound
healing pattern of gene expression in pterygium. Genes
encoding for extracellular matrix, structural and adhesion
molecules including wound healing related proteins, col-
lagen subtypes, keratin 6A and fibronectin were signifi-
cantly up-regulated in pterygium. Other up-regulated
proteins like small proline rich protein 1B (SPRR1B),
CD24, S100 calcium binding protein, SPARC, TFF1,
SPRR1B and SERPINB13 also govern the wound healing
process and cornification of epithelium, again, supporting
the hypothesis of aberrant wound response in pterygium.
Fibronectin alternatively splice transcript with EDA, up-
regulated in our pterygial specimens, was shown to be up-
regulated in wound healing.[30] In order to further vali-
date this finding, semi-quantitative PCR was performed
on paired pterygial and conjunctival tissue specimens
from 3 patients to examine the level of fibronectin tran-
script with EDA. The results show that pterygium
Validation of microarray dataFigure 7
Validation of microarray data. Bar graph showing the correlation of microarray data with real time PCR transcript levels. 
Black bars represent number of folds of change by GeneChip experiment, gray bars represent the number of folds of change 
using real time PCR. A normalised ratio (Y-axis) of more than 1 indicates up-regulation in pterygium, whereas a ratio of less 
than 1 indicates down-regulation in pterygium. The X axis shows an arbitrarily selected panel of genes.Page 14 of 21
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compared to uninvolved conjunctiva (Figure 8C).
Our data also suggest that in pterygia formation, there
may be increased cellular proliferation and motility on
one hand, and reduced cell death on the other. Genes up-
regulated in pterygium include fibronectin (FN1),
CEACAM5 (CEA), CD24, SPARC, MSMB and TFF1.
CEACAM5 (CEA), a common cancer marker, was up-reg-
ulated 3.8-fold in pterygium. SPARC was known to have
anti-adhesive property, and induced cancer cell motil-
ity.[31] The transcripts coding for microseminoprotein
(MSMB) or PSP94[32] was up-regulated 3.6-fold, whereas
transcripts for calcium binding protein S100A8 was up-
regulated 5.7-fold in pterygium. Interestingly, in our anal-
ysis of tears from patients with pterygium, S100[18] pro-
Tissue localisation of important molecules in pterygiumF g re 8
Tissue localisation of important molecules in pterygium. Immunohistochemical staining images of uninvolved conjunc-
tiva and pterygium tissue. Nuclear position (and indirectly, tissue architecture) was shown using counter-staining with DAPI, in 
blue. The same magnification was used in all images: Scale Bar = 100 micrometers. A. Proteins with increased expression in 
pterygium. Staining for keratin 6A, CECAM5, CD24 and MUC5AC was shown in green and MSMB, in red. B. Proteins with 
decreased expression in pterygium. Staining for IGFBP3 and NR4A2 was shown in green and red respectively.Page 15 of 21
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restitution of epithelial cells and are abundantly secreted
onto the mucosal surface rapidly after mucosal injury.[33]
In contrast to the above, genes coding for apoptosis
(TGM2, IGFBP3 and DUSP1) were down-regulated in
pterygium, reinforcing the over-proliferative tendency in
pterygium.
The stress-inducible transcription regulator genes includ-
ing ATF3, BTG2, EGR1, ERG2, FOS, JUN, NR4A1 and
NR4A2 were surprisingly, down-regulated in pterygium
Important molecules in pterygium pathogenesisFigu e 9
Important molecules in pterygium pathogenesis. A and C. Ethidium bromide stained gel images from semi-quantitative 
reverse transcription polymerase chain reaction. A. Using specific primers against PSP57 (amplicon length of 452 bp) and PSP94 
(amplicon length of 350), PCR products corresponding to PSP94 could be visualised at 30 cycles, whereas PSP57 products 
could only be just detected at 40 cycles. The sequences were confirmed by sequencing the specific band after cutting the band 
and extraction of DNA. Note that in patients 1–3, PSP94 transcripts were up-regulated in pterygium relative to conjunctival 
controls. B. Western blot images, using specific antibodies against MSMB and GADPH (loading control). Note that the PSP 
proteins were up-regulated in pterygium relative to controls. C. The alternative spliced forms of fibronectin transcripts ED-A 
and ED-B were detected by visualisation of PCR products. Note that all forms of the transcripts were up-regulated in ptery-
gium compared to conjunctival controls.Page 16 of 21
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Table 5: Gene microarray data corresponding to detected tear proteins.
Name of gene corresponding to tear protein Genbank Accession No of fold change p value
A. Genes significantly regulated in pterygium
Prolactin-induced protein I NM_002652 2.149 0.000213
S100A8 (Calgranulin A) NM_002964 1.74 0.0000082
Defensin alpha A1 U73945 1.506 0.0149
S100 A9 NM_002965 1.442 0.00204
Hepatocellular carcinoma associated protein (PIGR) NM_002644 1.371 0.0299
Vimentin AI922599 1.278 0.0324
Beta-2 microglobulin NM_004048 1.188 0.0378
Cathepsin G NM_001911 1.141 0.00984
S100 A12 NM_005621 1.122 0.0268
Clusterin (Apolipoprotein J) AI982754 1.08 0.0287
Vitamin D binding protein NM_000583 1.052 0.0437
Cystatin SN NM_001898 0.946 0.0121
Histone 1b NM_005322 0.941 0.00456
Orosomucoid 1 (alpha 1 acid glycoprotein) NM_000607 0.94 0.0027
Anti-thrombin III D29832 0.937 0.000451
Beta actin X00351 0.888 0.0263
Proline rich Peptide NM_025263 0.864 0.00355
Ribonuclease 4 NM_002937 0.725 0.000675
Alpha-1-antitrypsin (SERPINA1) NM_000295 0.72 0.0399
Ceruloplasmin (ferroxidase) NM_000096 0.637 0.000375
Complement C3 NM_000064 0.607 0.00443
Lipophilin C (SCGB2A1) NM_002407 0.402 0.000045
B. Genes not significantly regulated in pterygium
IGHM protein L23517 0.89 0.0511
Lipophilin A NM_006552 0.955 0.073
Zn-alpha2-glycoprotein D90427 1.223 0.0788
Apolipoprotein A-I NM_000039 0.934 0.0874
Immunoglobulin kappa light M63438 0.559 0.0878
Mucin 7 L13283 1.023 0.0895
Lipocalin 1 NM_002297 0.949 0.135
Alpha-fibrinogen NM_021871 1.038 0.261
Transferrin A1073407 0.97 0.319
Proline rich 4 (lacrimal) NM_007244 0.959 0.32
Nasopharyngeal carcinoma associated proline rich protein 4 NM_007244 0.959 0.32
Lactoferrin NM_002343 1.068 0.366
Complement Factor-B AF349679 1.048 0.386
Immunoglobulin J chain AV733266 0.707 0.398
cystatin SA NM_001322 0.977 0.415
Apolipoprotein A-IV NM_000482 0.977 0.442
Transthyretin AH62690 1.024 0.493
Lysozyme NM_020426 0.982 0.527
Complement factor H X04697 0.956 0.542
Annexin I NM_000700 0.959 0.583
Secretary leukocyte protease inhibitor NM_003064 0.944 0.592
Proline rich protein 5 NM_012390 1.145 0.597
Coagulation factor H (thrombin) NM_000506 0.979 0.6
Neutrophil elastase NM_001972 0.99 0.68
Apolipoprotein H NM_000042 1.013 0.691
Hemopexin BC005395 1.013 0.7
Albumin AF116645 1.007 0.8
Haptoglobin NM_005143 1.005 0.836
Basic proline rich protein X07882 1.004 0.905
Note: the study did not have expression data for the genes corresponding to the following tear proteins: defensins HNP-2 and HNP-3, lacritin and 
DMBT1.
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mind however, that our tissue specimens may represent
chronic UV stimulation. The expression of these transcrip-
tion factors may very well be elevated shortly after the
commencement of the initial stimulus.
The transcript level of immunoglobulin subunit in ptery-
gium was relatively lower as compared to uninvolved con-
junctiva. This does not support a role for B cell mediated
immunity in pterygium formation. However, the co-
expression of some immunoglobulin genes (Figure 4)
may have some biological significance, such as an immu-
nological basis for the inappropriate wounding response.
Possible mechanisms of pterygia recurrence
One hypothesis is that a low level of inflammation may
stimulate epithelial and fibroblast cell migration due to
factors such as SPN [see Additional file 3A]. This allows
continuation of inflammatory factors and cytokines to be
produced, potentiating a cycle [see Additional file 3B].
Factors such as SPN are unique to recurrence only, since
they were up-regulated compared to primary pterygium
cases.
In an alternative hypothesis, the formation of an exuber-
ant scar or a 'go' signal, may or may not be coupled with
a reduction of 'stop' or inhibitory signals. One such 'stop
signal' may be the MSMB protein. Any up-regulation of
this anti-metastatic gene in pterygium could give an inhib-
iting signal to slow the growth rate in pterygium. When
Table 6: Comparison of microarray analysis between two studies
Gene Fold change in John-Aryankalayil et al Fold change in our study
Significantly regulated in current study (p < 0.05)
SILV (silver homolog) 2.2 2.3
CD31 (PECAM1) 2.1 2.2
C5orf13 2.5 2.2
RBP1 3.6 2.0
Von Willebrand factor 2.5 2.0
RAB31 2.0 1.7
Clathrin (CLTB) 2.4 1.7
DAB2 2.1 1.5
S100 A9 (calgranulin B) 2.2 1.4






CD32 receptor 2.9 1.2
mRNA, clone AL050154 2.8 1.1
CLIC2 0.5 1.1
Prostaglandin F2alpha receptor 3.2 1.1
Not significantly regulated in current study (p > 0.05)
NDRG4 3.1 1.1
Carbonic anhydrase CA1 0.5 1.1
ABCG1 2.3 1.1
ADPRTL2 2.3 1.1
Casein kinase II 2.5 1.0
Collagen III 4.1 1.0
Fibronectin 8.5 1.0
LZTR1 2.2 1.0
Collagen VI 2.1 1.0
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may also be reduced, encouraging the remnants of fibrous
tissue to proliferate more aggressively, attaining the phe-
notype of recurrent pterygium. This may also explain the
success of conjunctival autographs as adjunctive proce-
dure after excision of the lesion in the prevention of recur-
rence. The graft tissue may 'replenish' any surgically-
induced loss of 'stop' signals. In support of this hypothe-
sis, the level of MSMB was significantly depressed in recur-
rent compared to primary pterygia.
Strengths and Limitations
The strengths of this study include the use of a variety of
analytical approaches to interpret the microarray data.
The tissue specimens have been harvested in a center
which manages a high volume of such disease. Samples
have been processed in a very standardized fashion,
obtained from patients with accurate clinical diagnoses.
One limitation of the study is that we did not evaluate p53
and related genes such as the Vasoendothelial growth fac-
tor (VEGF). Pterygia specimens contained a mixture of cell
types whereas un-involved conjunctiva consisted largely
of epithelial tissue. Therefore, any observations concern-
ing differential gene expression could be related to differ-
ences in composition of cells as well as to pathological
processes.
We did not notice regional differences in the intensity of
CD24 immunofluorescent staining along the length of
the pterygium epithelium on longitudinal section [see
Additional file 7]. However, we cannot conclusively state
that there is no difference in the pattern of CD24 expres-
sion between the head and the body of the pterygium.
Since the limits of the pterygium body was defined clini-
cally by the surgeon, we were uncertain if the bulk of the
pterygium body was available for immunohistology.
Since we did not obtain temporally located pterygia in
this study, our findings may not be applicable to this less
frequently occurring type of pterygia.
Specimens analysed were at the later stage of pterygium
formation when surgical removal was needed. No data at
the early stage of disease were available for investigation.
In addition to these limitations, there are inherent limita-
tions with hieuristic and even more deterministic meth-
ods of analyzing global gene expression. For example, the
results of the k-means clustering depend arbitrarily on the
initial number of clusters and the number of iterations.
However, we attempt to reduce the effects of these short-
comings by employing a variety of different data-mining
techniques and interpreting results as a whole and not in
isolation. We drew conclusions based on findings that are
consistent between different procedures and refrained
from over-interpretation of isolated anomalies.
If changes in global gene expression in cases of recurrent
pterygium do not occur until a very late time point, it may
not be possible to predict recurrence of the condition by
analysing the tissue obtained during the time of first exci-
sion. However, the gene expression data may still be use-
ful for understanding the biology of recurrence. The tear
protein analysis[18] also has limitations. It is difficult to
determine whether the detected proteins were physiologi-
cal, related to the surgical trauma, or arising from the dis-
ease. Nevertheless the 22 significantly up-regulated genes
that have products in human tears may be potential
biomarkers for the disease.
Potential applications
This study illustrates that an unbiased global gene expres-
sion approach is useful to address the disease mechanisms
in a controversial condition. Further studies on more
specimens may allow the use of a sub-set of genes to prog-
nosticate lesions. Non-surgical treatment for pterygium
currently does not exist. Since wound healing and matrix
dysregulation is a major theme, known modulators of
wound healing may be explored in pterygium in a tar-
geted way, using topical application. Other novel proc-
esses require further evaluation. Studies in the regulation
of cell adhesion by CD24 and mucous processing path-
ways are required to understand pterygium formation.
Studies are also required to elicit the origin of the overly-
ing epithelium in pterygium tissue.
Nevertheless, our study suggests that after resection of the
initial tumor, clinicians can modify treatment in selected
patients based on objective criteria after analysing tumor
gene expression or tumor proteins.
Conclusion
Based on differential gene profiling in pterygium, it can be
concluded that an aberrant wound healing process is the
major pathogenetic process in pterygial formation. The
other secondary processes such as cornification and
attempted barrier formation may be compensatory in
nature. This contrasts sharply with frank malignant neo-
plasms, where gene expression signatures are dominanted
by increased proliferation, reduced apoptosis, cell cycling
anomalies and genomic instability. The existence of an
aggressive phenotype to account for post excision recur-
rence may be related to an imbalance of growth signals
rather than due to mere prolongation of the stimulus that
initiated primary pterygial formation.
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